These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28832761)

  • 1. Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5.
    Yu Z; Cheng H; Zhu H; Cao M; Lu C; Bao S; Pan Y; Li Y
    Braz J Med Biol Res; 2017 Aug; 50(10):e6147. PubMed ID: 28832761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
    Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
    Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.
    Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
    Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
    Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
    Exp Cell Res; 2013 Dec; 319(20):3140-9. PubMed ID: 24012960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
    Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
    Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salinomycin reduces epithelial-mesenchymal transition-mediated multidrug resistance by modifying long noncoding RNA HOTTIP expression in gastric cancer cells.
    Mao Z; Wu Y; Zhou J; Xing C
    Anticancer Drugs; 2019 Oct; 30(9):892-899. PubMed ID: 30882398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin.
    Kim KY; Kim SH; Yu SN; Park SK; Choi HD; Yu HS; Ji JH; Seo YK; Ahn SC
    Mol Med Rep; 2015 Aug; 12(2):1898-904. PubMed ID: 25892525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells.
    Liu L; Wang Q; Mao J; Qin T; Sun Y; Yang J; Han Y; Li L; Li Q
    Chem Biol Interact; 2018 Dec; 296():145-153. PubMed ID: 30273566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas.
    Liffers ST; Tilkorn DJ; Stricker I; Junge CG; Al-Benna S; Vogt M; Verdoodt B; Steinau HU; Tannapfel A; Tischoff I; Mirmohammadsadegh A
    BMC Cancer; 2013 Oct; 13():490. PubMed ID: 24144362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin.
    Borlle L; Dergham A; Wund Z; Zumbo B; Southard T; Hume KR
    BMC Vet Res; 2019 Jan; 15(1):36. PubMed ID: 30678671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formononetin sensitizes glioma cells to doxorubicin through preventing EMT via inhibition of histone deacetylase 5.
    Liu Q; Sun Y; Zheng JM; Yan XL; Chen HM; Chen JK; Huang HQ
    Int J Clin Exp Pathol; 2015; 8(6):6434-41. PubMed ID: 26261519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity.
    Hermawan A; Wagner E; Roidl A
    Oncol Rep; 2016 Mar; 35(3):1732-40. PubMed ID: 26708059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells.
    Li J; Liu H; Yu J; Yu H
    Mol Med Rep; 2015 Jul; 12(1):192-8. PubMed ID: 25684678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells.
    Kusunoki S; Kato K; Tabu K; Inagaki T; Okabe H; Kaneda H; Suga S; Terao Y; Taga T; Takeda S
    Gynecol Oncol; 2013 Jun; 129(3):598-605. PubMed ID: 23500085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salinomycin suppresses TGF-β1-induced epithelial-to-mesenchymal transition in MCF-7 human breast cancer cells.
    Zhang C; Lu Y; Li Q; Mao J; Hou Z; Yu X; Fan S; Li J; Gao T; Yan B; Wang B; Song B; Li L
    Chem Biol Interact; 2016 Mar; 248():74-81. PubMed ID: 26896736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
    Ponnusamy L; Mahalingaiah PKS; Singh KP
    Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
    Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
    Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salinomycin and dichloroacetate synergistically inhibit Lewis lung carcinoma cell proliferation, tumor growth and metastasis.
    Skeberdytė A; Sarapinienė I; Krasko JA; Barakauskienė A; Žilionytė K; Prokarenkaitė R; Sužiedėlis K; Bukelskienė V; Jarmalaitė S
    Biochem Biophys Res Commun; 2020 Mar; 523(4):874-879. PubMed ID: 31955885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of AMPK-related kinase 5 (ARK5) enhances cisplatin cytotoxicity in non-small cell lung cancer cells through regulation of epithelial-mesenchymal transition.
    Li M; Zheng C; Xu H; He W; Ruan Y; Ma J; Zheng J; Ye C; Li W
    Am J Transl Res; 2017; 9(4):1708-1719. PubMed ID: 28469776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.